Takara BioFRA:TF2 71 PB Ratio is 1.27 as of Jun. 26, 2026, which is 59% below its 10-year median of 3.08. GuruFocus rates FRA:TF2 with a GF Score™ of 71/100 and a GF Value™ of €4.51 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,233 Biotechnology companies, Takara Bio ranks better than 75.18% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Takara Bio's share price is €5.95. Takara Bio's Book Value per Share for the quarter that ended in Mar. 2026 was €4.69. Hence, Takara Bio's PB Ratio of today is 1.27.
Warning Sign:
Takara Bio Inc stock PB Ratio (=1.33) is close to 2-year high of 1.37.
The historical rank and industry rank for Takara Bio's PB Ratio or its related term are showing as below:
FRA:TF2'
s PB Ratio Range Over the Past 10 Years
Min: 0.79 Med: 3.08 Max: 6.24
Current: 1.33
During the past 13 years, Takara Bio's highest PB Ratio was 6.24. The lowest was 0.79. And the median was 3.08.
FRA:TF2's PB Ratio is ranked better than 75.18% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:TF2: 1.33
During the past 12 months, Takara Bio's average Book Value Per Share Growth Rate was -10.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -2.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 8.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Takara Bio was 19.10% per year. The lowest was -2.60% per year. And the median was 2.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Takara Bio PB Ratio Related Terms
Takara Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Takara Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Takara Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takara Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Takara Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Takara Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Takara Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Takara Bio (FRA:TF2) has a PB Ratio of 1.27 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Takara Bio and its competitors. This is 59% below median its historical median of 3.08. Over the past decade, Takara Bio's PB Ratio has ranged from 0.79 to 6.24. According to the industry distribution chart, Takara Bio ranks #306 out of 1233 companies in the Biotechnology industry, placing it in the top 24.8%.
Is Takara Bio's PB Ratio too high?
Takara Bio's current PB Ratio of 1.27 is 59% below median its 10-year median of 3.08. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 6.24. The Biotechnology industry median PB Ratio is 2.80. Takara Bio's value of 1.27 is 54.6% below this industry median. Based on the distribution chart, Takara Bio ranks #306 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Takara Bio has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Takara Bio's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Takara Bio ranks #306 out of 1233 companies for PB Ratio. This places Takara Bio in the top 25% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Takara Bio's value of 1.27 is 54.6% below this benchmark. Historically, Takara Bio's own PB Ratio has ranged from 0.79 to 6.24 over the past decade. While the company's 10-year median is 3.08 vs. the industry median of 2.80, Takara Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Takara Bio's current PB Ratio of 1.27 is 54.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Takara Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takara Bio's current PB Ratio is 1.27, which is 59% below median its own 10-year median of 3.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takara Bio stock overvalued right now?
Based on GuruFocus' analysis, Takara Bio (FRA:TF2) is currently considered Significantly Overvalued. The stock's GF Value™ is €4.51, compared to a current price of €5.95 — trading 31.9% above its estimated fair value. The current PB Ratio is 1.27, which is 59% below median its 10-year median of 3.08 and 54.6% below the Biotechnology industry median of 2.80. Takara Bio's overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Takara Bio (FRA:TF2), the current PB Ratio is 1.27 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takara Bio (FRA:TF2) Overvalued in 2026?
Based on GuruFocus' analysis, Takara Bio stock appears to be overvalued.
The current stock price of €5.95 is trading 31.9% above its estimated GF Value™ of €4.51.
GuruFocus considers Takara Bio to be Significantly Overvalued.
Key valuation signals for FRA:TF2:
PB Ratio: 1.27 (59% below median its 10-year median of 3.08)
GF Value™: €4.51 vs. price of €5.95 (31.9% above fair value)
Industry Position: 54.6% below the Biotechnology median (#306 of 1233)
No single metric tells the full story. See the FRA:TF2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takara Bio Inc is a biotechnology company that develops gene therapy procedures. The company reports in three business segments: Bioindustry, Gene therapy, and AgriBio. Takara's bioindustry business provides research reagents, scientific instruments, and various contracted services to universities and companies around the world. The company's gene therapy business is focused on treating cancer and HIV. Its AgriBio business aims to leverage biotechnologies in the food ingredient field, including large-scale mushroom production. The vast majority of Takara's revenue is derived from its bioindustry segment.
71GF Score
Get the complete analysis for FRA:TF2
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:TF2 has been successfully added to your 
